Fabry Disease [clinicaltrials_resource:00e24aaffd391fffb7d3ca954363cf05]
Vasodilation in Patients With Fabry's Disease [clinicaltrials:NCT00001774]PET Scans in Normal Volunteers and Patients With Fabry Disease [clinicaltrials:NCT00005111]Data Collection in Women With Fabry Disease [clinicaltrials:NCT00030134]Alpha-Galactosidase A Replacement Therapy for Fabry Disease [clinicaltrials:NCT00048906]Registry of Fabry Disease - A Multicenter Observational Study [clinicaltrials:NCT00055016]clinicaltrials:NCT00068107An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease [clinicaltrials:NCT00071877]clinicaltrials:NCT00074958A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease [clinicaltrials:NCT00074971]clinicaltrials:NCT00074984Alternative Dosing and Regimen of Replagal to Treat Fabry Disease [clinicaltrials:NCT00075244]clinicaltrials:NCT00081497clinicaltrials:NCT00084084Replagal Enzyme Replacement Therapy for Adults With Fabry Disease [clinicaltrials:NCT00097890]Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity [clinicaltrials:NCT00106912]clinicaltrials:NCT00140621Enzyme Replacement Therapy in Fabry Disease [clinicaltrials:NCT00149318]Neuropathic Pain and Fabry Disease [clinicaltrials:NCT00168974]clinicaltrials:NCT00196716Fabry Disease Registry [clinicaltrials:NCT00196742]A Study of AT1001 in Patients With Fabry Disease [clinicaltrials:NCT00214500]clinicaltrials:NCT00230607A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease. [clinicaltrials:NCT00233870]A 24-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease [clinicaltrials:NCT00283933]A 12-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease [clinicaltrials:NCT00283959]A 12-Week Safety and Pharmacodynamic Study of AT1001 in Female Patients With Fabry Disease [clinicaltrials:NCT00304512]A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency. [clinicaltrials:NCT00312767]Antiproteinuric Agents and Fabry Disease [clinicaltrials:NCT00343577]An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease [clinicaltrials:NCT00357786]clinicaltrials:NCT00413595clinicaltrials:NCT00446862clinicaltrials:NCT00455104Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease [clinicaltrials:NCT00487630]Open Label Long-term Safety Study of AT1001 in Patients With Fabry Disease Who Have Completed a Previous AT1001 Study [clinicaltrials:NCT00526071]A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms [clinicaltrials:NCT00701415]clinicaltrials:NCT00837824clinicaltrials:NCT00864851Viennese Prevalence Study of Anderson-Fabry Disease [clinicaltrials:NCT00871611]Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease [clinicaltrials:NCT00925301]Fabry Screening Study [clinicaltrials:NCT01019629]
condition [clinicaltrials_vocabulary:condition]
Analysis of the Nervous System in Patients With Fabry's Disease [clinicaltrials:NCT00001491]Vasodilation in Patients With Fabry's Disease [clinicaltrials:NCT00001774]PET Scans in Normal Volunteers and Patients With Fabry Disease [clinicaltrials:NCT00005111]Data Collection in Women With Fabry Disease [clinicaltrials:NCT00030134]Alpha-Galactosidase A Replacement Therapy for Fabry Disease [clinicaltrials:NCT00048906]Registry of Fabry Disease - A Multicenter Observational Study [clinicaltrials:NCT00055016]clinicaltrials:NCT00068107An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease [clinicaltrials:NCT00071877]clinicaltrials:NCT00074958A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease [clinicaltrials:NCT00074971]clinicaltrials:NCT00074984Alternative Dosing and Regimen of Replagal to Treat Fabry Disease [clinicaltrials:NCT00075244]clinicaltrials:NCT00081497clinicaltrials:NCT00084084Replagal Enzyme Replacement Therapy for Adults With Fabry Disease [clinicaltrials:NCT00097890]Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity [clinicaltrials:NCT00106912]clinicaltrials:NCT00140621Enzyme Replacement Therapy in Fabry Disease [clinicaltrials:NCT00149318]Neuropathic Pain and Fabry Disease [clinicaltrials:NCT00168974]clinicaltrials:NCT00196716Fabry Disease Registry [clinicaltrials:NCT00196742]A Study of AT1001 in Patients With Fabry Disease [clinicaltrials:NCT00214500]clinicaltrials:NCT00230607A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease. [clinicaltrials:NCT00233870]A 24-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease [clinicaltrials:NCT00283933]A 12-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease [clinicaltrials:NCT00283959]A 12-Week Safety and Pharmacodynamic Study of AT1001 in Female Patients With Fabry Disease [clinicaltrials:NCT00304512]A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency. [clinicaltrials:NCT00312767]Antiproteinuric Agents and Fabry Disease [clinicaltrials:NCT00343577]An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease [clinicaltrials:NCT00357786]clinicaltrials:NCT00413595clinicaltrials:NCT00414583clinicaltrials:NCT00446862clinicaltrials:NCT00455104Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease [clinicaltrials:NCT00487630]Open Label Long-term Safety Study of AT1001 in Patients With Fabry Disease Who Have Completed a Previous AT1001 Study [clinicaltrials:NCT00526071]A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms [clinicaltrials:NCT00701415]Anderson-Fabry Disease in Chronic Kidney Disease Patients Not on Renal Replacement Therapy [clinicaltrials:NCT00728364]clinicaltrials:NCT00837824clinicaltrials:NCT00864851
condition browse [clinicaltrials_vocabulary:condition-browse]
Analysis of the Nervous System in Patients With Fabry's Disease [clinicaltrials:NCT00001491]Vasodilation in Patients With Fabry's Disease [clinicaltrials:NCT00001774]PET Scans in Normal Volunteers and Patients With Fabry Disease [clinicaltrials:NCT00005111]Data Collection in Women With Fabry Disease [clinicaltrials:NCT00030134]Alpha-Galactosidase A Replacement Therapy for Fabry Disease [clinicaltrials:NCT00048906]Registry of Fabry Disease - A Multicenter Observational Study [clinicaltrials:NCT00055016]clinicaltrials:NCT00068107An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease [clinicaltrials:NCT00071877]clinicaltrials:NCT00074958A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease [clinicaltrials:NCT00074971]clinicaltrials:NCT00074984Alternative Dosing and Regimen of Replagal to Treat Fabry Disease [clinicaltrials:NCT00075244]clinicaltrials:NCT00081497clinicaltrials:NCT00084084Replagal Enzyme Replacement Therapy for Adults With Fabry Disease [clinicaltrials:NCT00097890]Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity [clinicaltrials:NCT00106912]clinicaltrials:NCT00140621Enzyme Replacement Therapy in Fabry Disease [clinicaltrials:NCT00149318]Neuropathic Pain and Fabry Disease [clinicaltrials:NCT00168974]clinicaltrials:NCT00196716Fabry Disease Registry [clinicaltrials:NCT00196742]A Study of AT1001 in Patients With Fabry Disease [clinicaltrials:NCT00214500]clinicaltrials:NCT00230607A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease. [clinicaltrials:NCT00233870]A 24-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease [clinicaltrials:NCT00283933]A 12-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease [clinicaltrials:NCT00283959]A 12-Week Safety and Pharmacodynamic Study of AT1001 in Female Patients With Fabry Disease [clinicaltrials:NCT00304512]A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency. [clinicaltrials:NCT00312767]Antiproteinuric Agents and Fabry Disease [clinicaltrials:NCT00343577]An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease [clinicaltrials:NCT00357786]clinicaltrials:NCT00413595clinicaltrials:NCT00414583clinicaltrials:NCT00446862clinicaltrials:NCT00455104Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease [clinicaltrials:NCT00487630]Open Label Long-term Safety Study of AT1001 in Patients With Fabry Disease Who Have Completed a Previous AT1001 Study [clinicaltrials:NCT00526071]A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms [clinicaltrials:NCT00701415]Anderson-Fabry Disease in Chronic Kidney Disease Patients Not on Renal Replacement Therapy [clinicaltrials:NCT00728364]clinicaltrials:NCT00837824clinicaltrials:NCT00864851
condition mesh [clinicaltrials_vocabulary:condition-mesh]
Fabry Disease [clinicaltrials_resource:00e24aaffd391fffb7d3ca954363cf05]
Bio2RDF identifier
00e24aaffd391fffb7d3ca954363cf05
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:00e24aaffd391fffb7d3ca954363cf05
identifier
clinicaltrials_resource:00e24aaffd391fffb7d3ca954363cf05
title
Fabry Disease
@en
type
label
Fabry Disease [clinicaltrials_resource:00e24aaffd391fffb7d3ca954363cf05]
@en
Fabry Disease